HYBRID EVENT: You can participate in person at Boston, Massachusetts, USA or Virtually from your home or work.
Medicine and Vaccine for Covid-19
The common symptoms of COVID-19 are a coughing, fever and breathing problems. If you have a number of symptoms, you can most likely treat them at home, with the way you would do for a cold or the flu. Most of the people recover from COVID-19 without taking hospital care. Doctors and Scientists are continuously working on it to make new medicines and test few existing medicines to see whether they can treat COVID-19. Simultaneously there are a number of things that can relieve symptoms, both at home and at the hospital.
The Covid-19 vaccines are planned to provide active immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease 2019 (COVID-19).
Committee Members
Stefan Gluck
Vice President, Global Medical Affairs at Celgene Corporation, United States
Hemanta Kumar Kar
Kalinga Institute of Medical Sciences(KIMS), India
Sudhakar Bangera
Fellow-vaccinology managing partner AILEEN clinical research services AILEEN, India
Mayra Ramos Suzarte
Center of Molecular Immunology, Cuba IVC 2023 Speakers
Sushmita Koley
Senior Scientist Bio-Rad Laboratories, United States
Joe Smyser
The Public Good Projects, United States
Paul Van Buynder
Griffith University, Australia
Daniel Becker
KyooBe Tech GmbH, Germany
Patricia Canteri de Souza
State University of Londrina, BrazilSubmit your abstract Today
Title : Vaccines and monoclonal antibodies in the prolonged treatment of non-small cell lung cancer: 20 years of follow-up
Mayra Ramos Suzarte, Center of Molecular Immunology, Cuba
Title : Observational study post emergency use authorization of itolizumab in the treatment of COVID-19
Mayra Ramos Suzarte, Center of Molecular Immunology, Cuba
Title : Vaccine for AML: 2023 and beyond
Stefan Gluck, Vice President, Global Medical Affairs at Celgene Corporation, United States
Title : Purification process development of COVID antigens to identify sera needed for plasma therapy
Sushmita Koley, Senior Scientist Bio-Rad Laboratories, United States
Title : Lessons that can be learned from the rollout of the COVID-19 vaccine and the acceptance of vaccination from healthcare professionals, frontline workers and patients that need to be considered in developing a vaccine
Regina Au, BioMarketing Insight, United States
Title : Lessons learned for the future of social listening to address vaccine misinformation
Joe Smyser, The Public Good Projects, United States
Title : Why Low-Energy-Electron Irradiation might be a potential game changer for vaccine development, manufacturing, and pandemics prevention
Daniel Becker, KyooBe Tech GmbH, Germany
Title : National immunization management system- NIMS
Kashif Zulfiqar, Project Manager - NADRA, Pakistan
Title : Medicinal synthetic aluminum-magnesium silicate {Al4 (SiO4)3 + 3Mg2SiO4?2Al2 Mg3 (SiO4)3} effective for: Viral diseases; Tumors; Antimicrobial resistant infections
Maduike Chiehiura Onwubiko Ezeibe, Michael Okpara University of Agriculture, Nigeria
Title : Moving the needle for covid-19 vaccinations in Nigeria through leadership, accountability, and transparency
Fejiro Chinye Nwoko, Nigeria Solidarity Support Fund, Nigeria